Curriculum Vitae
Bertolani Arianna is Junior Lecturer of Government, Health & Not for Profit at SDA Bocconi School of Management.
She collaborated in the implementation and realization of research and training projects in the field of drug policies, market access and economic evaluations. As a member of the Pharmaceutical Observatory (OSFAR) of CeRGAS – SDA Bocconi, she contributes every year to the drafting of a Report that photographs the national and international situation regarding pharmaceutical spending and policy.
Her research is mainly focused on the analysis of pharmaceutical spending (public and private), on the evaluation of the main national and international policies related to the pharmaceutical context, on the analysis of the costs of diseases and on the economic evaluations of health technologies.
Author of several chapters related to health and pharmaceutical spending published on the OASI Report (Osservatorio sulle Aziende e sul Sistema Sanitario Italiano) and some articles published in important international and national journals, such as Clinical Therapeutics and Global & Regional Health Technology Assessment (GRHTA). Among the most recent: «Implementation of Value-based Pricing for Medicines (Clinical Therapeutics 2020)» and «The hospitalization burden of influenza: just the tip of the iceberg? Influenza-driven admission to hospitals: the Italian case. The hospitalization burden of influenza in Italy (GRHTA 2018)».
After graduating in Pharmaceutical Biotechnology at the University of Milan and obtaining a Ph.D. in Chemical Engineering and Industrial Chemistry at the Politecnico di Milano, Arianna earned a Master in Healthcare Management (MiMS) at SDA Bocconi. Currently, she is Junior Lecturer and works within the Government, Health and Not for Profit division (GHNP) of SDA Bocconi.
Books
- Politiche del farmaco ed impatto sulla spesa: gli effetti di quindici anni di decentramento nel SSN, con un focus sull’adozione di forme alternative di distribuzione dei farmaci, Rapporto OASI 2017;
- La spesa sanitaria: composizione ed evoluzione, Rapporto OASI 2017.
Articles
- Budget Impact Analysis of rituximab biosimilar in Italy in the hospital and payer perspective. Financial impact of rituximab biosimilar in Italy, GRHTA (2018) – in submission;
- Patients’ Associations and HTA for medicines: actual and future role in Italy. Patients’ Associations and HTA for medicines in Italy, GRHTA (2018) – in submission;
- The hospitalization burden of influenza: just the tip of the iceberg? Influenza-driven admission to hospitals: the Italian case (GRHTA 2018);
- Halogen bonding modulates hydrogel formation from Fmoc amino acids. CrystEngComm, 19, 1870-1874 (2017);
- Crystal structure of the DFNKF segment of human calcitonin unveils aromatic interactions between phenylalanines. Chemistry - A European Journal, 23, 2051-2058 (2017);
- Supramolecular amplification of amyloid self-assembly by iodination, Nature Communications, 6:7574 (2015);
- An efficient method for the lipase-catalysed resolution and in-line purification of racemic flurbiprofen in a continuous-flow reactor, Journal of Molecular Catalysis B: Enzymatic, 84, 78-82 (2012).